QTVascular

80 Robinson Road #02-00 Singapore 068898
Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com

FOR IMMEDIATE RELEASE

QT Vascular announces global expansion of distribution agreements

- Chocolate PTA® balloon to be sold in Italy, Austria, Turkey and Australia
- Agreement widens Chocolate® PTA balloon's availability in Europe and Australia; showcases growing recognition of the balloon's clinical benefits
- Management to continue to expand its distribution channels in more countries

Singapore, 15 October 2014 – Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group"), has announced that it has signed distribution agreements for the sales of its Chocolate PTA® balloon catheter in Italy, Austria, Turkey, and Australia.

Designed to deliver optimal results without a permanent implant, Chocolate® PTA represents a breakthrough in PTA balloon catheter design. Its unique Nitinol constraining structure (CS) is designed to facilitate a controlled uniform balloon expansion and disperse expansion forces along an increased contact surface area in order to induce less acute trauma on the vessel wall compared to conventional PTA balloons.

The Chocolate® PTA balloon catheter was recently featured prominently in a satellite symposium titled "Beyond Balloons and Stents" at the Transcatheter Therapeutics Conference in Washington, DC. During this symposium, Dr. Jihad Mustapha, Director of Cardiovascular Catheterization Laboratories at Metro Health Hospital in Wyoming, Michigan, presented the interim results of the Chocolate BAR registry. The Chocolate BAR registry has now enrolled a total of over 480 patients (one of the largest peripheral registries), including over 220 patients in the highly complex below-the-knee (BTK) cohort. Only 2% of the patients in this challenging cohort required a bail out stent and at 3 months, the rate of amputation-free survival was a high 98%, while the rate of re-intervention was only 5%.

Dr. Eitan Konstantino, the Group's Chief Executive Officer, commented, ***"We are gratified that there is growing recognition across many countries of the clinical benefits that Chocolate® PTA can provide to critically ill patients. We look forward to expanding the availability of Chocolate® PTA to more countries, especially in Asia, as we receive more regulatory approvals."***

- End –

80 Robinson Road #02-00 Singapore 068898
Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com

About Peripheral Artery Disease

Peripheral artery disease (PAD) is caused by the build-up of fatty substances that collect and adhere to the linings of the arteries, in a process known as atherosclerosis. The build-up causes the internal lining of the artery to thicken, narrowing the artery and limiting blood flow to vital tissues and organs. Commonly affected arteries include those located in the legs, arms, neck and kidneys. The vast majority of patients with PAD also have significant concomitant coronary artery disease (CAD) and a high proportion of morbidity and mortality in these patients is related to myocardial infarction, ischemic stroke or cardiovascular death. PAD is estimated to affect 202 million people worldwide (1).

About Coronary Artery Disease

Coronary artery disease occurs when the coronary arteries (the arteries surrounding the heart) become narrowed by a buildup of plaque, including cholesterol, fatty deposits, calcium, and other substances. As plaque accumulates over time, the diameter of the arterial lumen, or inner channel, narrows, resulting in reduced or stopped blood flow. When this occurs in arteries supplying blood to the heart, it can cause chest pain, a heart attack, or even death.

About QT Vascular Ltd.

QT Vascular Ltd. (QT Vascular) is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. The Company works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes. QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC, in Pleasanton, California. The Company was listed on the Catalist Board of the Singapore Exchange Securities Trading Limited on 29 April 2014.

References:

(1) "Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis." 19 Oct 2013. The Lancet.

For more information, please refer to: http://www.qtvascular.com/

Issued for and on behalf of QT Vascular Ltd.
by Financial PR Pte Ltd
Kamal SAMUEL, kamal@financialpr.com.sg
Mark LIN, marklin@financialpr.com.sg
Tel: (65) 6438 2990 Fax: (65) 6438 0064

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

80 Robinson Road #02-00 Singapore 068898
Tel: +65 6438 2990 Fax: +65 66438 0064 Web: www.qtvascular.com

The Company was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the relevant rules of the SGX-ST. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Mark Liew, Managing Director, Corporate Finance, at 20 Cecil Street, #21-02 Equity Plaza, Singapore 049705, telephone +65 6229 8088.